New Path Molecular Research Competitors and Similar CompaniesClear all
New Path Molecular Research's competitors and similar companies include SillaJen, Alphamab Oncology, G1 Therapeutics and X4 Pharmaceuticals.
 New Path Molecular Research New Path Molecular Research is a company that specializes in the chemical synthesis of complex functional molecules. |  SillaJen SillaJen is a biotechnology company focused on engineering and developing oncolytic virus immunotherapeutics. |  G1 Therapeutics G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. |  X4 Pharmaceuticals X4 Pharmaceuticals (formerly known as Arsanis) is a biopharmaceutical company that provides drug development services. | ||
Founding Date | Founding Date 2015 | Founding Date 2003 | Founding Date 2009 | Founding Date 2008 | Founding Date 2010 |
Type | Type Private | Type Public | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations Cambridge, GB HQ | Locations KR HQ San Francisco, US | Locations Suzhou Shi, CN HQ | Locations Durham, US HQ | Locations Boston, US HQ Wien, AT |
Employees | Employees 620% increase | Employees 4316% increase | Employees 42 | Employees 17015% increase | Employees 1005% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 377.2 m | Valuation ($) 83.9 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) ₩9.2b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $82.5m (FY, 2023) | Revenue (est.) $6.5m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods (₩1k) (FY, 2025) | Cost of goods N/A | Cost of goods $7.2m (FY, 2023) | Cost of goods $5.8m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit ₩9.9b (FY, 2025) | Gross profit N/A | Gross profit $75.3m (FY, 2023) | Gross profit $743k (FY, 2025) |
Net income | Net income N/A | Net income (₩24.2b) (FY, 2025) | Net income N/A | Net income ($48m) (FY, 2023) | Net income N/A |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 12m | Total funding raised $ 160m | Total funding raised $ 289.6m | Total funding raised $ 64.5m |
For sources of this data, please see the company profile
View Company Profiles
SillaJen
HQ
KR
Employees
43↑ 16% increase
SillaJen is a biotechnology company focused on engineering and developing oncolytic virus immunotherapeutics.
View company
Alphamab Oncology
HQ
Suzhou Shi, CN
Employees
42
Alphamab Oncology is a clinical-stage biopharmaceutical company.
View companyG1 Therapeutics
HQ
Durham, US
Employees
170↑ 15% increase
G1 Therapeutics is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer.
View companyX4 Pharmaceuticals
HQ
Boston, US
Employees
100↑ 5% increase
X4 Pharmaceuticals (formerly known as Arsanis) is a biopharmaceutical company that provides drug development services.
View company